Podium Presentations


Podium Session I MONDAY, 26 OCTOBER: 10:15 - 11:15
ADHERENCE/COMPLIANCE STUDIES
AC1	PERSISTENCE WITH ANTIHYPERTENSIVE DRUG CLASSES; INFLUENCE OF METHOD ASSUMPTIONS
	Nguyen NH, Vegter S, Visser ST, Postma MJ, de Jong-van den Berg LTW, Boersma C
	University of Groningen, Groningen, The Netherlands
AC2	SUCCESS FACTORS IMPROVING PATIENT COMPLIANCE BEHAVIOUR - EMPIRICAL FINDINGS FROM EUROPE
	Schäfer C
	Johannes Gutenberg-University of Mainz, Mainz, Germany
AC3	NON-ADHERENCE IN OUTPATIENT THROMBOSIS PROPHYLAXIS AFTER MAJOR ORTHOPAEDIC SURGERY
	Wilke T
	University of Wismar, Wismar, Germany
AC4	A RETROSPECTIVE COHORT STUDY OF MEDICATION ADHERENCE TO TREATMENT OF OSTEOPOROSIS IN A SWEDISH POPULATION
	Landfeldt E¹, Borgström F¹, Robbins S², Ström O¹
	¹i3 Innovus, Stockholm, Sweden, ²Amgen Europe GmbH, Zug, Switzerland

CANCER STUDIES I
CN1	HOW MUCH DOES ADJUSTING FOR HEALTH-RELATED QUALITY OF LIFE MATTER IN COST-EFFECTIVENESS ANALYSIS? A COMPARISON OF COST/LIFE YEAR AND COST/QALY ESTIMATES FOR CANCER INTERVENTIONS
	Greenberg D, Cohen JT, Fang C, Neumann PJ
	Tufts Medical Center, Boston, MA, USA
CN2	ECONOMIC EVALUATION OF THE CHEK2 GENOTYPING AND PERSONALIZED BREAST CANCER SCREENING IN THE POLISH HEALTH CARE SYSTEM
	Orlewska E¹, Lubinski J²
	¹Centrum Farmakoekonomiki, Warsaw, Poland, ²Pomeranian Medical University, Szczecin, Poland
CN3	COST-EFFECTIVENESS OF SORAFENIB IN UNRESECTABLE AND/OR METASTATIC RENAL CELL CARCINOMA IN TURKEY
	Tatar M¹, Akbulut H²
	¹Hacettepe University, Ankara, Turkey, ²Ankara University Medical School, Ankara, Turkey
CN4	COST-EFFECTIVENESS OF PEMETREXED IN FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PORTUGAL
	Pinto CG¹, Manaças M², Miguel LS³
	¹Technical University of Lisbon, Lisboa, Portugal, ²Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal, ³Research Centre on the Portuguese Economy - CISEP, Lisboa, Portugal

IMPACT OF DRUG EXPENDITURE CONTROL
DE1	MARKET CONCENTRATION AND ITS CROSS-LINKAGE WITH THE CONSUMPTION OF ACE INHIBITORS AND ARBS
	Zhang JX¹, Tao J² ¹Virginia Commonwealth University, Richmond, VA, USA, ²Virginia Commonwealth University, Richmond , VA, USA

DE2	INFLUENCE OF GENERIC DRUGS ON PROTON PUMP INHIBITOR PRESCRIPTION IN PRIMARY CARE
	Cammarota S¹, De Portu S², Citarella A¹, Menditto E¹, Cuomo R¹
	¹University of Naples, Naples, Italy, ²University Federico II, Naples, Italy
DE3	HAVE RECENT PHARMACEUTICAL REFORMS DAMAGED R&D?
	Trushin EF
	Queen Mary University of London, London, UK
DE4	PRESCRIPTION DRUG FORMULARIES AND COVERAGE: DOES A DRUG BY ANY OTHER NAME SMELL AS SWEET?
	Hsu J, Price M, Fung V
	Kaiser Permanente, Oakland, CA, USA

MENTAL HEALTH - MODELING STUDIES
MH1	A DISCRETE EVENT SIMULATION MODEL IN MAJOR DEPRESSIVE DISORDER – COST-EFFECTIVENESS ANALYSIS OF AGOMELATINE
	Félix J¹, Almeida J¹, Varandas P²
	¹Exigo Consultores, Alhos Vedros, Lisbon, Portugal, ²Hospital dos Lusíadas, Lisbon, Portugal
MH2	THE COST-EFFECTIVENESS OF OPPORTUNISTIC SCREENING AND MINIMAL CONTACT PSYCHOTHERAPY TO PREVENT DEPRESSION IN PRIMARY CARE PATIENTS
	Van den Berg M¹, Smit F², Vos T³, Van Baal P⁴
	¹National Institute for Public Health and the Environment, Bilthoven, The Netherlands, ²Trimbos Institute (The Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands, ³University of Queensland, Brisbane, Australia, ⁴National Institute for Public Health and the Enviroment, Bilthoven, The Netherlands
MH3	ANTIPSYCHOTIC USE AND DIABETES: A NESTED CASE-CONTROL ANALYSIS IN A COHORT OF NEW ANTIPSYCHOTIC USERS
	Moisan J¹, Desjardins O², Turgeon M³, Grégoire JP¹
	¹Université Laval, Québec, QC, Canada, ²Bristol-Myers Squibb Canada, St-Laurent, QC, Canada, ³Faculté de pharmacie, Université Laval, Québec, QC, Canada
MH4	COMORBID DEPRESSION IN PATIENTS DIAGNOSED WITH TYPE 2 DIABETES MELLITUS (T2DM): EFFECTS ON QUALITY OF LIFE AND RESOURCE USE
	Purayidathil FW, Gupta S, Wagner S
	Consumer Health Sciences International (a KantarHealth Company), Princeton, NJ, USA

UTILITY MEASUREMENTS STUDIES
UT1	VALUING EQ-5D USING TIME TRADE-OFF IN FRANCE
	Chevalier J¹, De Pouvourville G²
	¹Institut Gustave Roussy, Villejuif Cedex, France, ²ESSEC Business School, Cergy Pontoise Cedex, France
UT2	PARADIGM LOST: A CONCEPTUAL AND EMPIRICAL OBITUARY CHRONICLING THE DEMISE OF CARDINAL UTILITY MEASUREMENTNT
	Kind P
	University of York, York, UK
UT3	HEALTHY-DAYS TIME EQUIVALENTS FOR OUTCOMES OF ACUTE ROTAVIRUS INFECTIONS
	Hauber AB¹, Johnson FR¹, Cook JR², Mohamed AF¹, Gonzalez JM¹, Walter E³
	¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Merck and Co. Inc, North Wales, PA, USA, ³Duke University, Durham, NC, USA
UT4	DEVELOPING AND PRELIMINARY TESTING OF AN OFFICIAL FIVE-LEVEL VERSION OF EQ-5D
	Herdman M¹, Gudex C², Lloyd A³, Janssen B⁴, Kind P⁵, Parkin D⁶, Bonsel GJ⁷, Badia X⁸
	¹Insight Consulting & Research, Mataró, Barcelona, Spain, ²Odense University Hospital, Odense, Denmark, ³Oxford Outcomes Ltd, Oxford, Oxfordshire, UK, ⁴EuroQol Group Executive Office, Rotterdam, The Netherlands, ⁵University of York, York, UK, ⁶City University, London, UK, ⁷Erasmus Medical Centre, Rotterdam, n/a, The Netherlands, ⁸IMS Health, Barcelona, Spain


Podium Session II MONDAY, 26 OCTOBER: 14:00 - 15:00
CANCER STUDIES II
CN5	COSTS OFT QALYS GAINED IN A PALLIATIVE CARE UNIT (PCU) IN GERMANY
	Schuler US¹, Schubert BT², Haag C¹
	¹University of Dresden, Dresden, Saxony, Germany, ²St .Joseph Stift Hospital, Dresden, Saxony, Germany
CN6	TREATMENT-RELATED TOXICITIES IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
	Yood MU¹, Wang F(², Zhao Z², Alford SH³, Oliveria S¹, Wells K³, Phillips S⁴, Ali H³, O'Malley C⁵, Barber B⁶
	¹Epi Source, hamden, CT, USA, ²Amgen Inc, Thousand Oaks, CA, USA, ³Henry Ford Health System, Detroit, MI, USA, ⁴Epi Source, Hamden, CT, USA, ⁵Amgen, Inc, Thousand Oaks, CA, USA, ⁶Amgen Inc., Thousand Oaks, CA, USA
CN7	TREATMENT VARIATION COMPLICATES REAL-WORLD PHARMACOECONOMICS: DAILY CLINICAL PRACTICE OF BORTEZOMIB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
	Franken M¹, Gaultney J¹, Huijgens P², Redekop W¹, Uyl-de Groot C¹
	¹Erasmus University Medical Center, Rotterdam, The Netherlands, ²VU University Medical Center, Amsterdam, The Netherlands
CN8	METHODOLOGICAL ISSUES OF CONTROL ARM ADJUSTMENTS FOR COMPARATIVE EFFECTIVENESS ASSESSMENTS: AN EXAMPLE BASED ON THE COMPARISON OF FIRST-LINE BEVACIZUMAB + INTERFERON ALPHA-2A VS SUNITINIB IN RENAL CELL CARCINOMA
	Schwander B¹, Mickisch GH², Walzer S³, Siebert U⁴
	¹AiM GmbH Assessment in Medicine, Schopfheim, Germany, ²Center of Operative Urology Bremen, Bremen, Germany, ³F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland, ⁴UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i.T, Austria

ECONOMIC EVALUATION AND REIMBURSEMENT DECISIONS I
EE1	USING IQWIG'S EFFICIENCY FRONTIER APPROACH FOR THE ECONOMIC EVALUATION OF HEAPTITIS C TREATMENT – A PILOT AND FEASIBILITY STUDY COMMISSIONED BY IQWIG
	Siebert U, Mühlberger N, Conrads-Frank A, Sroczynski G, Schwarzer R
	UMIT - University for Health Sciences, Hall, Austria
EE2	DEAR POLICYMAKER: HAVE YOU MADE UP YOUR MIND?
	Koopmanschap M¹, Stolk E², Koolman XH³
	¹Erasmus MC, Rotterdam, The Netherlands, ²Erasmus Medical Center, Rotterdam, The Netherlands, ³Delft University of Technology, Delft, The Netherlands
EE3	IS NICE TOO NASTY? A COMPARISON OF ANTICANCER DRUG COVERAGE DECISIONS IN THE UNITED STATES AND UK
	Mason AR¹, Drummond MF¹, Ramsey SD², Campbell JD³, Raisch DW⁴
	¹University of York, York, N. Yorkshire, UK, ²Fred Hutchinson Cancer Research Center, Seattle, WA, USA, ³University of Washington, Seattle, WA, USA, ⁴University of New Mexico College of Pharmacy, Albuquerque, NM, USA
EE4	MARKET ACCESS IN GERMANY: WHERE NEXT?
	Zoellner YF¹, Schaefer M²
	¹Mapi Values, Houten, The Netherlands, ²Charité University Medicine, Berlin, Germany

MODELING METHODS I
MO1	COHORT MODELLING - IS THE APPROACH TOO OLD FOR THE ELDERLY?
	Ethgen O¹, Demarteau N², Standaert BA²
	¹University of Liège, Liège, Belgium, ²GlaxoSmithKline Biologicals, Rixensart, Belgium
MO2	IMPROVING COST-EFFECTIVENESS ANALYSES OF BEHAVIOURAL INTERVENTIONS BY USING COGNITIVE INTERMEDIATE OUTCOMES: A PILOT STUDY
	Prenger R¹, Pieterse ME¹, Braakman-Jansen LM¹, van der Palen J², Seydel ER¹
	¹University of Twente, Enschede, The Netherlands, ²Medisch Spectrum Twente Hospital, Enschede, The Netherlands
MO3	R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL IMPLEMENTED IN MICROSOFT EXCEL AND R.
	Bischof M, Lim ME, Ferrusi IL, Burke N, Blackhouse G, Goeree R, Tarride JE
	McMaster University, Hamilton, ON, Canada
MO4	BAYESIAN GENERALIZED LINEAR MODELLING OF THE RELATIONSHIP BETWEEN HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX AND HEALTH UTILITIES INDEX MARK III IN EARLY AND LATE RHEUMATOID ARTHRITIS: DATA FROM THE PREMIER AND ARMADA TRIALS
	Vanness D¹, Roy S², Benedict A³, Cifaldi M²
	¹United BioSource Corporation, Madison, WI, USA, ²Abbott Laboratories, Abbott Park, IL, USA, ³United BioSource Corporation, London, UK

PATIENT PREFERENCE STUDIES
PP1	A SYSTEMATIC REVIEW OF THE ANALYTIC HIERARCHY PROCESS IN HEALTH CARE DECISION MAKING
	Hummel JM, IJzerman MJ
	University of Twente, Enschede, The Netherlands
PP2	PATIENT PREFERENCES FOR BENEFIT-RISK TRADEOFFS AMONG POST-TRANSPLANT OUTCOMES IN END-STAGE RENAL DISEASE
	Johnson FR¹, Hauber AB¹, Mohamed AF¹, Gonzalez JM²
	¹RTI Health Solutions, Research Triangle Park, NC, USA, ²RTI HEalth Solutions, Research Triangle Park, NC, USA
PP3	WHAT DIMENSIONS ARE IMPORTANT TO PATIENTS IN THEIR EXPERIENCE OF CONTINUITY OF CARE? A STUDY OF PATIENTS' PREFERENCES USING A DISCRETE CHOICE EXPERIMENT
	Kjaer T¹, Bech M¹, Draborg E¹, Mollerup M²
	¹University of Southern Denmark, Odense, Denmark, ²Odense University Hospital, Odense, Denmark
PP4	LIVES WORTH LIVING: OLDER SMOKERS' STATED PREFERENCES FOR LONGEVITY
	Johnson FR¹, Smith VK², Smith GA³, Gonzalez JM⁴
	¹RTI International, Research Triangle Park, NC, USA, ²Arizona State University, Tempe, AZ, USA, ³University of Michigan, Ann Arbor, MI, USA, ⁴RTI Health Solutions, Research Triangle Park, NC, USA

VACCINES - COST EFFECTIVENESS ANALYSIS STUDIES
VA1	SEVEN, TEN OR THIRTEEN? THE COST-UTILITY OF INFANT VACCINATION WITH A 7-, 10- OR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN THE NETHERLANDS
	Vemer P¹, de Greeff SC², Schouls LM², Al MJ¹, de Melker H²
	¹Erasmus MC, Rotterdam, The Netherlands, ²National Institute for Public Health and Environment (RIVM), Bilthoven, The Netherlands
VA2	A HEALTH ECONOMIC EVALUATION OF A NEW HERPES ZOSTER (HZ) VACCINE FOR THE PREVENTION OF HZ AND POST-HERPETIC NEURALGIA (PHN) IN BELGIUM
	Annemans L¹, Papageorgiou M², Martin M³, Bresse X⁴
	¹Ghent University, Ghent, Belgium, ²i3 Innovus, Athens, Greece, ³i3 Innovus, Uxbridge, Middlesex, UK, ⁴Sanofi Pasteur MSD, Lyon, France
VA3	GLOBAL MEASLES ERADICATION: COST-EFFECTIVENESS AND IMPLICATIONS FOR GHANA, 2020-2049
	Garrison L¹, Bauch CT², Babigumira JB¹
	¹University of Washington, Seattle, WA, USA, ²University of Guelph, Guelph, ON, Canada
VA4	HEALTH ECONOMIC EVALUATION OF A NOVEL INTRADERMAL INFLUENZA VACCINE IN TWO EUROPEAN COUNTRIES
	Reygrobellet C¹, Hudeckova H², Kristufkova Z³, Kyncl J⁴
	¹Sanofi pasteur, Lyon, France, ²Jessenius Medical Faculty Comenius University, Bratislava, Slovakia, Slovak Republic, ³Faculty of Public Health, Slovak Medical University, Bratislava, Slovak Republic, ⁴National Institute of Public Health , Praha, Praha 10, Czech Republic

Podium Session III MONDAY, 26 OCTOBER: 15:15 - 16:15
HEALTH CARE DECISION-MAKER'S CASE STUDIES
CASE1	DESIGNING AND IMPLEMENTING OUTCOME-BASED REIMBURSEMENT SCHEMES: EXPERIENCE FROM HUNGARY
	Dankó D, Molnár MP, Berta G
	National Health Insurance Fund Administration (OEP), Budapest, Hungary
CASE2	REVIEW OF THE EARLY EXPERIENCE OF THE NEW NICE SCIENTIFIC ADVICE PROGRAMME
	Phillips S, Doss S, Longson C
	NICE, Manchester, UK
CASE3	THE SLOVAK EXPERIENCE IN THE INTERNATIONAL PRICE BENCHMARKING FOR PRESCRIPTION DRUGS
	Filko M¹, Szilagyiova P²
	¹Ministry of Finance of the Slovak Republic, Bratislava, Slovak Republic, ²Pfizer Slovakia, Bratislava, Slovak Republic
CASE4	ASSESSMENT AND APPRAISAL IN THE NETHERLANDS
	Delwel GO¹, Goettsch WG¹, Cucic C², Steenland E², Terhell L², Vingerhoed-van Aken BE²
	¹CVZ Healthcare Insurance Board, Diemen, The Netherlands, ²Netherlands Organisation for Health Research and Development (ZonMw), The Hague, The Netherlands

ECONOMIC EVALUATION AND REIMBURSEMENT DECISIONS II
EE5	THE SEESAW OF COST-EFFECTIVENESS THRESHOLDS: HOW RELAXED REQUIREMENTS FOR LATER LINES OF TREATMENT WILL INCREASE HURDLES FOR NEW THERAPIES
	Liwing J, Lothgren M
	Janssen-Cilag AB, Sollentuna, Sweden
EE6	INCORPORATING EQUITY IN COST-EFFECTIVENESS ANALYSIS: A SYSTEMATIC REVIEW
	Johri M¹, Norheim OF²
	¹Université de Montréal, Montreal, QC, Canada, ²University of Bergen, Bergen, Norway
EE7	A DISCRETE CHOICE EXPERIMENT COMPARING PUBLIC AND DECISION-MAKER STATED PREFERENCES FOR PHARMACEUTICAL SUBSIDY DECISIONS
	Whitty JA, Scuffham PA, Rundle-Thiele SR
	Griffith University, Brisbane, Queensland, Australia
EE8	BRIDGING HEALTH TECHNOLOGY ASSESSMENT WITH MULTICRITERIA DECISION ANALYSIS (MCDA) AND AN ETHICAL FRAMEWORK FOR COMPLEX DECISIONS: CASE STUDY OF GROWTH HORMONE FOR TURNER SYNDROME
	Goetghebeur MM¹, Wagner M¹, Khoury H¹, Rindress D¹, Grégoire JP², Deal C³
	¹BioMedCom Consultants Inc, Montreal, QC, Canada, ²Université Laval, Québec, QC, Canada, ³CHU Ste-Justine & University of Montréal, Montreal, QC, Canada

MODELING METHODS II
MO5	THE USE OF SURVIVAL ANALYSES FOR COST-EFFECTIVENESS MODELS: AN EVALUATION OF METHODS USED IN NICE APPRAISALS
	Guyot P¹, Ouwens M²
	¹Mapi Values Netherlands BV, Houten, The Netherlands, ²Mapi Values Netherlands B.V., Houten, The Netherlands
MO6	MODELLING COST EFFECTIVENESS OF DRUGS THAT DELAY DISABILITY PROGRESSION IN MULTIPLE SCLEROSIS: A NOVEL APPROACH
	Skedgel C¹, Brown MG², Andreou P¹, Kirby S²
	¹Dalhousie University, Halifax, NS, Canada, ²Capital Health Nova Scotia, Halifax, NS, Canada
MO7	EVALUATION OF A BAYESIAN COMPREHENSIVE DECISION-ANALYTICAL MODELLING FRAMEWORK IN CHRONIC HEPATITIS C
	Cawston H¹, Aballéa S², Cure S¹
	¹i3 Innovus, Uxbridge, UK, ²i3 Innovus, Nanterre, France
MO8	MARGINAL STRUCTURAL MODELS FOR COMPARING THE EFFECTIVENESS OF MULTIPLE TREATMENTS IN OBSERVATIONAL STUDIES
	Desai R, Johnson M
	University of Houston, Houston, TX, USA

PRO/QOL METHODS - CROSS CULTURAL ADAPTATION
PR1	A LATENT GENERAL GROWTH MIXTURE MODEL FOR HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSON DISEASE ACROSS 36 MONTH
	Reese JP¹, Klotsche J², Winter Y¹, Wittchen HU², Dodel R¹
	¹Philipps-University, Marburg, Germany, ²Technische Universität Dresden, Dresden, Germany
PR2	DEVELOPMENT AND PSYCHOMETRIC PROPERTIES OF A PEDIATRIC PERCEIVED COGNITIVE FUNCTION ITEM BANK (PEDSPCF)
	Lai JS¹, Zelko F², Butt Z¹, Cella D¹, Magasi S¹, Goldman S²
	¹Northwestern University, Chicago, IL, USA, ²Children's Memorial Hospital, Chicago, Chicago, IL, USA
PR3	FIBROMYALGIA FATIGUE – DEVELOPMENT OF A CONCEPTUAL MODEL BASED ON QUALITATIVE PATIENT INTERVIEWS
	Mease P¹, Humphrey L², Arbuckle R², Williams DA³, Danneskiold-Samsoe B⁴, Gilbert C⁵
	¹Seattle Rheumatology Associates, Seattle, WA, USA, ²Mapi Values Ltd, Bollington, UK, ³University of Michigan, Ann Arbor, MI, USA, ⁴Frederiksberg Hospital, Frederiksberg, Denmark, ⁵Pfizer Ltd, Sandwich, UK
PR4	LINEAR SCORING RULES FOR PATIENT REPORTED OUTCOMES AND PATIENT PREFERENCES
	Mohamed AF¹, Hauber AB¹, Johnson FR²
	¹RTI Health Solutions, Research Triangle Park, NC, USA, ²RTI International, Research Triangle Park, NC, USA

VACCINES - MODELING STUDIES
VA5	INDIVIDUALLY-BASED DYNAMIC MODELING OF INFECTIOUS DISEASES: COST-EFFECTIVENESS OF ADOLESCENT PERTUSSIS BOOSTER VACCINATION FOR THE NETHERLANDS
	de Vries R, Postma M
	University of Groningen, Groningen, The Netherlands
VA6	INTEGRATED DYNAMIC TRANSMISSION/COST-EFFECTIVENESS MODEL FOR INFLUENZA A AND B PART I: DEVELOPMENT OF AN INTEGRATED MODEL
	Pitman RJ¹, Leeuwenkamp O²
	¹Oxford Outcomes Ltd, Oxford, Oxfordshire, UK, ²MedImmune, Cambridge, Cambridgeshire, UK
VA7	COMPARISON OF DIFFERENT STATIC AND DYNAMIC SIMULATION TECHNIQUES FOR THE INFLUENCE OF CHILDREN PNEUMOCOCCAL VACCINATION
	Endel G¹, Schiller - Frühwirth I¹, Popper N², Zauner G², Breitenecker F³
	¹Hauptverband der Österreichischen Sozialversicherungsträger, Vienna, Vienna, Austria, ²DWH - Simulation Services, Vienna, Vienna, Austria, ³Vienna University of Technology, Vienna, Vienna, Austria
VA8	HOW SHOULD HEALTH GAINS OF VACCINATION STRATEGIES BE DISCOUNTED?
	Westra TA¹, Rogoza R², Daemen T¹, Wilschut JC¹, Postma MJ³
	¹University Medical Center Groningen, Groningen, The Netherlands, ²i3 Innovus, Burlington, ON, Canada, ³University of Groningen, Groningen, The Netherlands

Podium Session IV MONDAY, 26 OCTOBER: 16:30 - 17:30
COST STUDIES
CO1	ESTIMATE AVERAGE MEDICAL COSTS IN THE PRESENCE OF RIGHT-CENSORING
	Guan S¹, Peeters P², Pedotti P¹, Van Engen AK¹
	¹Quintiles Consulting, Hoofddorp, The Netherlands, ²Quintiles Consulting, Levallois-Perret, France
CO2	WITHDRAWN


CO3	INDIRECT SOCIAL COST OF MULTIPLE SCLEROSIS: RESULTS FROM A REAL-WORLD OBSERVATIONAL STUDY
	Kirzinger S¹, Halper J², Jeffery D³, Preblick R⁴, Bi YJ⁴, Bharmal M⁵, Jo H⁵
	¹University of Louisville, Louisville, KY, USA, ²MS Center at HNH, Teaneck, NJ, USA, ³Wake Forest University School of Medicine, Winston-Salem, NC, USA, ⁴Bayer HealthCare Pharmaceuticals, Inc., Health Economics, Outcome and Reimbursement (HEOR), Wayne, NJ, USA, ⁵Quintiles, Inc., Falls Church, VA, USA
CO4	MICRO-COSTING VS GROSS-COSTING IN THE ESTIMATION OF COSTS FOR THE PHARMACOECONOMIC EVALUATION OF GLAUCOMA IN KOREA
	Kang SH, Lee EK
	SookMyung Women's University, Seoul, South Korea

DIABETES STUDIES
DB1	USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING: POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH AND COMPLICATION RISK ESTIMATES
	Goeree R, Lim ME, Hopkins R, Blackhouse G, Tarride JE, Xie F, O'Reilly D
	McMaster University, Hamilton, ON, Canada
DB2	PERSISTENCE WITH BASAL SUPPORTED ORAL THERAPY - COMPARISON OF INSULIN GLARGINE VERSUS NPH INSULIN
	Quinzler R¹, Ude M², Franzmann A¹, Feldt S¹, Leuner K², Mueller WE², Dippel FW³, Schulz M⁴
	¹GIDE - German Institute for Drug Use Evaluation (DAPI), Eschborn, Hessen, Germany, ²Goethe-University, Frankfurt am Main, Hessen, Germany, ³Sanofi-Aventis, Berlin, Berlin, Germany, ⁴ABDA - Federal Union of German Associations of Pharmacists, Berlin, Berlin, Germany
DB3	USING ELECTRONIC MEDICAL RECORDS TO IDENTIFY UNDIAGNOSED DIABETES MELLITUS IN PRIMARY CARE PRACTICES
	Marelli C¹, Cload P², Ross S³, Kallenbach L⁴, Haas S⁵, Gunnarsson C⁶, Zyczynski T⁷
	¹GE HealthCare LTD, Bucks, Giles Bucks, England, ²GE HealthCare LTD, Bucks, Bucks, England, ³SDRoss Consulting, Cohasset, MA, USA, ⁴GE Healthcare Clinical Data Services, Plano, TX, USA, ⁵s2 Statistical Solutions, Inc., Cincinnati, OH, USA, ⁶S2 Statistical Solutions, Inc, Cincinnati, OH, USA, ⁷GE Healthcare, Princeton, NJ, USA
DB4	RISK OF STROKE OR MYOCARDIAL INFARCTION OF T2DM PATIENTS TREATED WITH PIOGLITAZONE OR NON-THIAZOLIDINEDIONE IN A MANAGED CARE SETTING IN THE UNITED STATES
	Sun SX¹, Vallarino C², Xu Y¹, Kupfer S², Bron M¹
	¹Takeda Pharmaceuticals International, Inc, Deerfield, IL, USA, ²Takeda Global Research and Development Center, Inc, Deerfield, IL, USA

MODELING METHODS - HANDLING UNCERTAINTY
MO9	HANDLING UNCERTAINTY IN THE CASE OF COMBINED END-POINTS
	Heeg BMS¹, Treur MJ², van Hout BA³
	¹Pharmerit Europe, Rotterdam, The Netherlands, ²PharMerit Europe, Rotterdam, Zuid-Holland, The Netherlands, ³Pharmerit Ltd, York, North Yorkshire, UK
MO10	EARLY MODELLING: METHODS IN THE ECONOMIC ANALYSIS OF PRE-PHASE II PRODUCTS
	Taylor M, Saxby R
	University of York, York, UK
MO11	WHEN DOES VALUE OF INFORMATION ANALYSIS ADD VALUE?
	Ishak KJ¹, Getsios D², Caro JJ²
	¹United BioSource Corporation, Montreal, QC, Canada, ²United BioSource Corporation, Lexington, MA, USA
MO12	COMPARISON OF THREE META-MODELS FOR UNCERTAINTY ANALYSIS
	Lieuw On MML¹, Heeg BMS², De Charro F², van Hout BA³
	¹Pharmerit, Rotterdam, Zuid-Holland, The Netherlands, ²Pharmerit Europe, Rotterdam, The Netherlands, ³Pharmerit Ltd, York, North Yorkshire, UK

PRO/QOL METHODS - DEVELOPMENT
PR5	TRANSLATION AND LINGUISTIC VALIDATION: EVIDENCE TO SUGGEST THAT AN IN-COUNTRY REVIEW IS NECESSARY
	Gergovich KB, Houchin C, Wild D
	Oxford Outcomes Ltd, Oxford, UK
PR6	PRESENTATION OF THE ACTIVITIES OF THE ISOQOL TRANSLATION AND CULTURAL ADAPTATION SPECIAL INTEREST GROUP (TCA-SIG)
	Conway K¹, Patrick DL², Martin M³, Eremenco S⁴, Petkova I¹
	¹MAPI Research Trust, Lyon, France, ²University of Washington, Seattle, WA, USA, ³Health Research Associates, Inc., Seattle, WA, USA, ⁴Evanston Northwestern Healthcare Research Institute, Evanston, IL, USA
PR7	EVALUATION OF ALTERNATIVE METHODS OF TRANSLATING PATIENT-REPORTED OUTCOME MEASURES
	McKenna SP¹, Hagell P², Hedin PJ³, Nyberg L²
	¹Galen Research, Manchester, UK, ²Lund University, Lund, Sweden, ³Central Hospital, FALUN, Sweden
PR8	VALIDATION OF THE PROQOL-HIV QUESTIONNAIRE IN LIGHT OF CROSS-CUTURAL DIFFERENCES FROM 5 CONTINENTS
	Duracinsky M¹, Acquadro C², Lalanne C², Herrmann S³, Berzins B⁴, Lecoeur S⁵, Diouf A⁶, Fournier-Nicolle I⁷, Lau J⁸, Schechter M⁹, Chassany O¹⁰
	¹Centre Hospitalier Universitaire de Bicetre, Le Kremlin-Bicetre, France, ²Hôpital Saint Louis, Paris, France, ³Royal Perth Hospital, Perth, Australia, ⁴Northwestern University, Chicago, Chicago, IL, USA, ⁵Programme for HIV Prevention and Treatment (PHPT), Chiang Mai, Thailand, ⁶Centre de Recherche Clinique de Fann (CRCFP), Dakar, Senegal, ⁷Hôpital Calmette, Phnom Penh, Cambodia, ⁸Chinese University of Hong Kong, Hong Kong, China, ⁹Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁰Assistance Publique - Hopitaux de Paris, Paris, France

WILLINGNESS TO PAY STUDIES
WP1	COMPARISON OF A DIRECT AND AN INDIRECT METHOD TO DERIVE WILLINGNESS TO PAY FOR COMPLEX HEALTH STATES IN OBSTETRICS
	Bijlenga D¹, Bonsel GJ², Birnie E²
	¹Academic Medical Centre, Amsterdam, The Netherlands, ²Erasmus Medical Centre, Rotterdam, The Netherlands
WP2	VALUE OF POSTOPERATIVE ACUTE PAIN CARE FOR PATIENTS OPERATED BY LAPAROTOMY IN A DEPARTMENT OF DIGESTIVE SURGERY IN A FRENCH UNIVERSITY HOSPITAL: A WILLINGNESS TO PAY STUDY
	Bocquet F¹, Thiriat N¹, Beaussier M¹, Aissou M¹, Preziosi C¹, Borget I², Tilleul P¹
	¹St-Antoine Hospital, Paris, France, ²Institut de Cancérologie Gustave Roussy, Villejuif, France
WP3	ASSESSING THE WILLINGNESS-TO-PAY (WTP) FOR INTRADERMAL INFLUENZA VACCINATION IN AUSTRALIA USING DISCRETE CHOICE METHODOLOGY
	Adams J¹, Price N², Mason G³
	¹IMS Health, St Leonards, NSW, Australia, ²Sanofi-Aventis, Sydney, NSW, Australia, ³Sanofi Pasteur, Sydney, NSW, Australia
PCV137	PREFERENCES OF PATIENTS, PHYSICIANS AND CAREGIVERS IN THE CHOICE OF ABDOMINAL AORTIC ANEURYSMS TREATMENT OPTIONS: THE PREFER STUDY
	Scalone L¹, Borghetti F², Faggioli G³, Stella A³, Cortesi P², Mantovani LG⁴
	¹University of Milan – Bicocca, Milan, Italy, ²University of Milan, Milan, Italy, ³Sant'Orsola Malpighi Hospital-University of Bologna, Bologna, Italy, ⁴University of Naples, Federico II, Naples, Italy